Candance Judkins
Psychiatric/Mental Health · Talladega, ALNPI 1679824973
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,988 and has fallen 87.7% since, to $368 in 2025.
Across 289 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$907
- Teva Pharmaceuticals USA, Inc.$885
- Otsuka America Pharmaceutical, Inc.$680
- AbbVie$679
- Neurocrine Biosciences, Inc.$486
- Alkermes, Inc.$461
- plus $1K from 8 others
What the payments were for
- Food & beverage$5,03494%
- Education$3136%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $907 |
| Teva Pharmaceuticals USA, Inc. | 56 | $885 |
| Otsuka America Pharmaceutical, Inc. | 31 | $680 |
| AbbVie | 50 | $679 |
| Neurocrine Biosciences, Inc. | 18 | $486 |
| Alkermes, Inc. | 23 | $461 |
| Indivior Inc. | 27 | $402 |
| Johnson & Johnson | 16 | $346 |
| Vanda Pharmaceuticals Inc. | 12 | $224 |
| Lundbeck LLC | 7 | $129 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Noven Therapeutics, LLC | 2 | $42 |
| Corium, LLC | 2 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,347 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 168 | $460,668 |
| IngrezzaValbenazine Tosylate | 34 | $287,936 |
| AustedoDeutetrabenazine | 24 | $182,490 |
| Invega TrinzaPaliperidone Palmitate | 19 | $180,152 |
| Risperdal ConstaRisperidone Microspheres | 37 | $73,050 |
| AristadaAripiprazole Lauroxil | 24 | $71,118 |
| VraylarCariprazine Hcl | 41 | $69,169 |
| Abilify MaintenaAripiprazole | 17 | $50,929 |
| CaplytaLumateperone Tosylate | 23 | $38,479 |
| Aripiprazole | 165 | $29,119 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,064 |
| Lurasidone Hcl | 39 | $16,877 |
| Risperidone ErRisperidone Microspheres | 11 | $16,211 |
| Fluphenazine Hcl | 59 | $7,630 |
| Fluphenazine Decanoate | 51 | $6,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $346 | $713,870224 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $486 | $287,93634 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $885 | $182,49024 claims |
| Alkermes, Inc.Aristada, Lybalvi | $461 | $88,18235 claims |
| AbbVieVraylar | $679 | $69,16941 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $680 | $50,92917 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $907 | $38,47923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Talladega
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Ian KinzerHuntsville$15K
- Latisha AliHoover$15K
- Taylor BarrettGadsden$15K
- Angela GarrardGadsden$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.